Abstract
Abiraterone acetate (CB 7630; CB7630; JNJ-212082), the 3β-acetate prodrug of abiraterone, is structurally related to ketoconazole and is being developed by Cougar Biotechnology as a hormonal therapy for advanced prostate and breast cancers. As a selective inhibitor of adrenal androgens, it is thought to be a safer product than existing second-line hormonal therapies. This review discusses the key development milestones and therapeutic trials of this drug.
MeSH terms
-
Abiraterone Acetate
-
Androgen Antagonists / pharmacology
-
Androgen Antagonists / therapeutic use*
-
Androstadienes / pharmacology*
-
Androstadienes / therapeutic use*
-
Animals
-
Antineoplastic Agents, Hormonal / pharmacology
-
Antineoplastic Agents, Hormonal / therapeutic use*
-
Drug Evaluation, Preclinical
-
Drugs, Investigational / pharmacology
-
Drugs, Investigational / therapeutic use*
-
Humans
-
Neoplasms / drug therapy*
-
Prodrugs / pharmacology
-
Prodrugs / therapeutic use*
Substances
-
Androgen Antagonists
-
Androstadienes
-
Antineoplastic Agents, Hormonal
-
Drugs, Investigational
-
Prodrugs
-
Abiraterone Acetate